1.Keane WF, Eknoyan G. Proteinuria, albuminuria, risk, assessment, detection, elimination (PARADE): a position paper of the National Kidney Foundation. Am J Kidney Dis 1999;33:1004–1010.
2.Orth SR, Ritz E. The nephrotic syndrome. N Engl J Med 1998;338:1202–1211.
3.Remuzzi G, Bertani T. Pathophysiology of progressive nephropathies. N Engl J Med 1998;339:1448–1456.
4.Abbate M, Benigni A, Bertani T, et al. Nephrotoxicity of increased glomerular protein traffic. Nephrol Dial Transplant 1999;14:304–312.
5.Gerstein HC, Mann JFE, Yi Q, et al. Albuminuria and the risk of cardiovascular events, death, and heart failure in diabetic and nondiabetic individuals. JAMA 2001;286:421–426.
6.Yuyun MF, Khaw K-T, Luben R, et al. A prospective study of microalbuminuria and incident coronary heart disease and its prognostic significance in a British population—the EPIC-Norfolk Study. Am J Epidemiol 2004;159:284–293.
7.Coresh J, Astor BC, Greene T, et al. Prevalence of chronic kidney disease and decreased kidney function in the adult US population. Third National Health and Nutrition Examination Survey. Am J Kidney Dis 2003;41:1–12.
8.Fuller CE, Threatte GA, Henry JB. Basic examination of urine, in Henry JB (ed): Clinical Diagnosis and Management by Laboratory Methods. Philadelphia, WB Saunders Co, 2001, ed 20, pp 373–376.
9.Hebert SC, Reilly RF Jr, Kriz W. Structural-functional relationships in the kidney, in Schrier RW (ed):Diseases of the Kidney and Urinary Tract. Philadelphia, Lippincott, Williams and Wilkins, 2001, ed 7, pp 3–57.
10.Lafayette RA, Perrone RD, Levey AS. Laboratory evaluation of renal function, in Schrier RW (ed):Diseases of the Kidney and Urinary Tract. Philadelphia, Lippincott, Williams and Wilkins, 2001, ed 7, pp 333–369.
11.K/DOQI clinical practice guidelines for chronic kidney disease: evaluation, classification and stratification. Am J Kidney Dis 2002;39(suppl 2):S1–S266.
12.Mundel P, Shankland SJ. Podocyte physiology and response to injury. J Am Soc Nephrol2002;13:3005–3015.
13.Devarajan P. Mechanisms of orthostatic proteinuria: lessons from a transplant donor. J Am Soc Nephrol 1993;4:36–39.
14.Ginsberg JM, Chang BS, Matarese RA, et al. Use of single voided urine samples to estimate quantitative proteinuria. N Engl J Med 1983;309:1543–1546.
15.Rodby RA, Rohde RD, Sharon Z, et al. The urine protein to creatinine ratio as a predictor of 24-hour urine protein excretion in type 1 diabetic patients with nephropathy. The Collaborative Study Group. Am J Kidney Dis 1995;26:904–909.
16.Taal MW, Brenner BM. Renoprotective benefits of RAS inhibition: from ACE I to angiotensin II antagonists. Kidney Int 2000;57:1803–1817.
17.Brenner BM. Remission of renal disease: recounting the challenge, acquiring the goal. J Clin Invest2002;110:1753–1758.
18.Campbell RC, Ruggenenti P, Remuzzi G. Halting the progression of chronic nephropathy. J Am Soc Nephrol 2002;13:S190–S195.
19.Brenner BM. Retarding the progression of renal disease. Kidney Int 2003;64:370–378.
20.Brewster UC, Perazella MA. The renin-angiotensin-aldosterone system and the kidney: effects on kidney disease. Am J Med 2004;116:263–272.
21.Wilmer WA, Rovin BH, Hebert CJ, et al. Management of glomerular proteinuria: a commentary. J Am Soc Nephrol 2003;14:3217–3232.
22.Lewis EJ, Hunsicker LG, Bain RP, et al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med 1993;329:1456–1462.
23.Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting-enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med 1996;334:939–945.
24.The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia). Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. Lancet 1997;349:1857–1863.
25.Ruggenenti P, Perna A, Gherardi G, et al. For the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN). Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Ramipril Efficacy in Nephropathy. Lancet 1998;352:1252–1256.
26.Ruggenenti P, Perna A, Benini AR, et al. For the Gruppo Italiano di Studi Epidemiologici in Nefrologia (GISEN): In chronic nephropathies prolonged ACE inhibition can induce remission: dynamics of time-dependent changes in GFR. J Am Soc Nephrol 1999;10:997–1006.
27.Lewis EJ, Hunsicker LG, Clarke WR, et al. Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes. N Engl J Med 2001;345:851–860.
28.Brenner BM, Cooper ME, de Zeeuw D, et al. Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy. N Engl J Med 2001;345:861–869.
29.Agodoa LY, Appel L, Bakris GL, et al. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial. JAMA 2001;285:2719–2728.
30.Nakao N, Yoshimura A, Morita H, et al. Combination treatment of angiotensin II receptor blocker and angiotensin-converting enzyme inhibitor in nondiabetic renal disease (COOPERATE): A randomized controlled trial. Lancet 2003;361:117–124.
31.Schrier RW, Estacio RO. The effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a pooled analysis of individual-patient data from 11 randomized, controlled trials. Ann Intern Med 2001;135:138–139.
32.Jafar TH, Schmid CH, Landa M, et al. Angiotensin-converting enzyme inhibitors and progression of nondiabetic renal disease. A meta-analysis of patient-level data. Ann Intern Med 2001;135:73–87.
33.Jafar TH, Schmid CH, Levey AS. Effect of angiotensin-converting enzyme inhibitors on progression of nondiabetic renal disease. Ann Intern Med 2002;137:298–299.
34.Jafar TH, Stark PC, Schmid CH, et al. Progression of chronic kidney disease: the role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition: a patient-level meta-analysis. Ann Intern Med 2003;139:244–252.
35.Ruggenenti P, Perna A, Gherardi G, et al. Renoprotective properties of ACE-inhibition in non-diabetic nephropathies with non-nephrotic proteinuria. Lancet 1999;354:359–364.
36.Eddy AA, Giachelli CM. Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 1995;47:1546–1557.
37.Abbate M, Zoja C, Corna D, et al. In progressive nephropathies, overload of tubular cells with filtered proteins translates glomerular permeability dysfunction into cellular signals of interstitial inflammation. J Am Soc Nephrol 1998;9:1213–1224.
38.Zoja C, Donadelli R, Colleoni S, et al. Protein overload stimulates RANTES production by proximal tubular cells depending on NF-kappa B activation. Kidney Int 1998;53:1608–1615.
39.Donadelli R, Zanchi C, Morigi M, et al. Protein overload induces fractalkine upregulation in proximal tubular cells through nuclear factor kB- and p38 mitogen-activated protein kinase-dependent pathways.J Am Soc Nephrol 2003;14:2436–2446.
40.Mogensen CE, Christensen CK. Predicting diabetic nephropathy in insulin-dependent patients. N Engl J Med 1984;311:89–93.
41.Messent JW, Elliott TG, Hill RD, et al. Prognostic significance of microalbuminuria in insulin-dependent diabetes mellitus: a twenty-three year follow-up study. Kidney Int 1992;41:836–839.
42.The Diabetes Control and Complications (DCCT) Research Group. Effect of intensive therapy on the development and progression of diabetic nephropathy in the Diabetes Control and Complications Trial.Kidney Int 1995;47:1703–1720.
43.The Microalbuminuria Study Group. Captopril reduces the risk of nephropathy in IDDM patients with microalbuminuria. Diabetologia 1996;39:587–593.
44.The ACE Inhibitors in Diabetic Nephropathy Trialist Group. Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data. Ann Intern Med 2001;134:370–379.
45.Parving H-H, Lehnert H, Bröchner-Mortensen J, et al. The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes. N Engl J Med 2001;345:870–878.
46.Perkins BA, Ficociello LH, Silva KH, et al. Regression of microalbuminuria in type 1 diabetes. N Engl J Med 2003;348:2285–2293.
47.Pedrinelli R, Dell'Omo G, Penno G, et al. Microalbuminuria, a parameter independent of metabolic influences in hypertensive men. J Hypertens 2003;21:1163–1169.
48.Palaniappan L, Carnethon M, Fortmann SP. Association between microalbuminuria and the metabolic syndrome: NHANES III. Am J Hypertens 2003;16:952–958.
49.U.S. Renal Data System. USRDS 2001 Annual Data Report: atlas of end-stage renal disease in the United States. National Institute of Diabetes and Digestive and Kidney Diseases 2001, Bethesda, MD.
50.Hostetter TH. Prevention of end-stage renal disease due to type 2 diabetes. N Engl J Med2001;345:910–912.
51.Haroun MK, Jaar BG, Hoffman SC, et al. Risk factors for chronic kidney disease: a prospective study of 23,534 men and women in Washington County, Maryland. J Am Soc Nephrol 2003;14:2934–2941.
52.Levey AS, Beto JA, Coronado BE, et al: Controlling the epidemic of cardiovascular disease in chronic renal disease: What do we know? Where do we go from here? National Kidney Foundation Task Force on Cardiovascular Disease. Am J Kidney Dis 1998;32:853–906.
53.Gaede P, Vedel P, Larsen N, et al. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med 2003;348:383–393.
54.Bennett PH, Haffner S, Kasiske BL, et al. Screening and management of microalbuminuria in patients with diabetes mellitus: recommendations to the Scientific Advisory Board of the National Kidney Foundation from an ad hoc Committee of the Council on Diabetes Mellitus of the National Kidney Foundation. Am J Kidney Dis 1995;25:107–112.
55.American Diabetes Association clinical practice recommendations 2003: diabetic nephropathy.Diabetes Care 2003;26(suppl 1):S94–S98.
56.Preventive Services Task Force, Guide to clinical preventive services. Report of the U.S. Preventive Services Task Force. Baltimore, Williams and Wilkins 1996, ed 2.
57.Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron1976;16:31–41.
58.Levey AS, Bosch JP, Lewis JB, et al. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Ann Intern Med
59.Ronco PM. Paraneoplastic glomerulopathies: new insights into an old entity. Kidney Int1999;56:355–377.
60.Management of glomerulonephritis. Kidney Int 1999;55(suppl 70):S1–S62.
61.Appel GB, Glassock RJ. Glomerular, vascular, tubulo-interstitial and genetic diseases. American Society of Nephrology, NephSAP (Nephrology Self-Assessment Program), Volume 1 Syllabus
, July 2002;13–46. (Accessed April 28, 2004 at http://www.asn-online.org
62.Fried LF, Orchard TJ, Kasiske BL. Effect of lipid reduction on the progression of renal disease: a meta-analysis. Kidney Int 2001;59:260–269.
63.Ravid M, Brosh D, Levi Z, et al. Use of enalapril to attenuate decline in renal function in normotensive, normoalbuminuric patients with type 2 diabetes mellitus: a randomized, controlled trial.Ann Intern Med 1998;128:982–988.
64.Golan L, Birkmeyer JD, Welch HG. The cost-effectiveness of treating all patients with type 2 diabetes with angiotensin-converting enzyme inhibitors. Ann Intern Med 1999;131:660–667.
65.Klahr S, Levey AS, Beck GJ, et al. Effects of dietary protein restriction and blood pressure control on the progression of chronic renal disease. N Engl J Med 1994;330:877–884.
66.Peterson JC, Adler S, Burkart JM, et al. Blood pressure control, proteinuria and the progression of renal disease: The Modification of Diet in Renal Disease Study. Ann Intern Med 1995;123:754–762.
67.Levey AS, Greene T, Beck GJ, et al. Dietary protein restriction and the progression of chronic renal disease: what have all the results of the MDRD study shown? J Am Soc Nephrol 1999;10:2426–2439.
68.Hilgers KF, Mann JFE. ACE inhibitors versus AT1 receptor antagonists in patients with chronic kidney disease. J Am Soc Nephrol 2002;13:1100–1108.
69.Zandbergen AAM, Baggen MGA, Lamberts SWJ, et al. Effect of losartan on microalbuminuria in normotensive patients with type 2 diabetes mellitus: a randomized clinical trial. Ann Intern Med2003;139:90–96.
70.Lacourciere Y, Belanger A, Godin C, et al. Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy. Kidney Int 2000;58:762–769.
71.Bakris GL, Siomos M, Richardson D, et al. ACE inhibition or angiotensin receptor blockade: impact on potassium in renal failure. Kidney Int 2000;58:2084–2092.
72.Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation and treatment of high blood pressure: the JNC 7 report. JAMA2003;289:2560–2571.
73.Chobanian AV, Bakris GL, Black HR. et al. The National High Blood Pressure Education Program Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure. Hypertension 2003;42:1206–1252.
74.Buter H, Hemmeldeer MH, Navis G et al. The blunting of the antiproteinuric efficacy of ACE inhibition can be restored by hydrochlorthiazide. Nephrol Dial Transplant
75.Smith AC, Toto R, Bakris GL. Differential effects of calcium channel blockers on size selectivity of proteinuria in diabetic glomerulopathy. Kidney Int
76.Ruggenenti P, Perna A, Benini R, et al. Effects of dihydropyridine calcium channel blockers, angiotensin-converting enzyme inhibition and blood pressure control on chronic nondiabetic nephropathies. J Am Soc Nephrol 1998;9:2096–2101.
77.Bakris GL. A practical approach to achieving recommended blood pressure goals in diabetic patients. Arch Intern Med 2001;161:2661–2667.
78.Laverman GD, Andersen S, Rossing P, et al. Dose-dependent reduction of proteinuria by losartan does not require reduction of blood pressure. J Am Soc Nephrol 2002;13:265A.
79.Piccoli A, Pillon L. The antiproteinuric effect of high-dose ramipril: still an open question. Kidney Int
80.Mogensen CE, Neldam S, Tikkanen I, et al. Randomised controlled trial of dual blockade of renin-angiotensin system in patients with hypertension, microalbuminuria, and non-insulin dependent diabetes: the candesartan and lisinopril microalbuminuria (CALM) study. BMJ 2000;321:1440–1444.
81.Jacobsen P, Andersen S, Jensen BR, et al. Additive effect of ACE inhibition and angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. J Am Soc Nephrol2003;14:992–999.
82.Jacobsen P, Andersen S, Rossing K, et al. Dual blockade of the renin-angiotensin system versus maximal recommended dose ACE inhibition in diabetic nephropathy. Kidney Int 2003;63:1874–1880.
83.Campbell R, Sangalli F, Perticucci E, et al. Effects of combined ACE inhibitor and angiotensin II antagonist treatment in human chronic nephropathies. Kidney Int 2003;63:1094–1103.
84.Rossing K, Christensen PK, Jensen BR, et al. Dual blockade of renin-angiotensin system in diabetic nephropathy: a randomized double-blind crossover study. Diabetes Care 2002;25:95–100.
85.Russo D, Minutolo R, Pisani A, et al. Coadministration of losartan and enalapril exerts additive antiproteinuric effect in IgA nephropathy. Am J Kidney Dis 2001;38:18–25.
86.Ruilope LM, Aldigier JC, Ponticelli C, et al. Safety of combination of valsartan and benazepril in patients with chronic kidney disease. European Group for the Investigation of Valsartan in Chronic Renal Disease. J Hypertens 2000;18:89–95.
87.Agarwal R. Add on angiotensin receptor blockade with maximal ACE inhibition. Kidney Int2001;59:2282–2289.
88.Chrysostomou A, Becker G. Spironolactone in addition to ACE inhibition to reduce proteinuria in patients with chronic kidney disease. N Engl J Med 2001;345:925–926.
89.Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-converting enzyme inhibitors and spironolactone: analysis of 25 cases. Am J Med 2001;110:438–441.
90.Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine. Is this a cause for concern?. Arch Intern Med
91.Dhondt AW, Vanholder RC, Ringoir SM. Angiotensin-converting enzyme inhibitors and higher erythropoietin requirement in chronic hemodialysis patients. Nephrol Dial Transplant 1995;10:2107–2109.
92.Vogt L, Navis G, de Zeeuw D. Renoprotection: a matter of blood pressure reduction or agent-characteristics?. J Am Soc Nephrol 2002;13:S202–S207.
93.Locatelli F, Del Vecchio L, D'Amico M, et al. Is it the agent or the blood pressure level that matters for renal protection in chronic nephropathies?. J Am Soc Nephrol 2002;13:S196–S201.
94.UK Prospective Diabetes Study Group: Efficacy of atenolol and captopril in reducing risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 39. BMJ 1998;317:713–720.